肝細胞癌藥物市場規模、佔有率和成長分析（按類型、藥物類別、最終用戶和地區分類）—產業預測（2026-2033 年）

全球肝細胞癌治療市場規模預計在 2024 年達到 15.2 億美元，從 2025 年的 16.4 億美元成長到 2033 年的 31.1 億美元，在預測期（2026-2033 年）內複合年成長率為 8.3%。

由於患者族群結構的變化、政府對癌症治療領域投入的增加以及標靶治療研發的進步，全球肝細胞癌（HCC）治療市場正經歷強勁成長。政府對醫療創新的日益重視推動了新治療方法的推出，包括針對肝癌的精準醫療，而肝癌領域目前仍處於低度開發狀態。早期診斷技術的改進以及免疫療法和聯合治療在醫療系統中的廣泛應用進一步促進了這一成長。精準腫瘤學的關鍵創新，包括基於生物標記的方法和新一代蛋白酪氨酸激酶抑制劑（TKI），正在改變HCC的治療方式。此外，基於人工智慧的藥物發現平台的出現也促進了新型HCC免疫療法的快速開發和評估。

推動全球肝細胞癌藥物市場發展的因素

全球肝細胞癌藥物市場主要受疾病盛行率上升的驅動，而疾病盛行率上升的主要原因是抗藥性慢性感染疾病（如B型和C型肝炎）的增加。酒精消費量量的增加，以及非酒精性脂肪肝和非酒精性脂肪性肝炎患者人數的增加（肥胖和糖尿病的日益流行加劇了這個健康問題），進一步加劇了這個問題。患者數量的成長以及對有效治療方法的需求，使得現有療法和創新治療方法都面臨著強勁的需求。

限制全球肝細胞癌藥物市場的因素

全球肝細胞癌治療市場面臨許多挑戰，主要原因是免疫療法和標靶治療的高昂費用，阻礙了患者獲得治療的機會，尤其是在中低收入地區。此外，成熟市場已實施衛生技術評估（HTA）政策，這可能會延長昂貴療法的報銷流程。這不僅限制了患者的治療機會，也阻礙了創新治療方法的及時推廣，即使其臨床療效已得到證實。因此，這些因素構成了一種限制市場環境，減少了肝細胞癌治療領域整體發展的機會。

肝細胞癌藥物市場的全球趨勢

全球肝細胞癌治療市場正呈現一個顯著趨勢：利用PD-1/PD-L1抑制劑、蛋白酪氨酸激酶抑制劑（TKI）和抗血管新生藥物的協同作用，而聯合治療正快速發展。整合了Lenvatinib和Bevacizumab等藥物的創新聯合治療正在推動臨床療效的改善，死亡風險的顯著降低便是明證。 FDA和EMA等監管機構加快核准，進一步促進了這些治療方法的應用，加速了這一趨勢。因此，這個快速成長的市場有望重塑肝細胞癌的治療模式，並推動患者預後和疾病管理的改善。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 一手和二手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 用例

全球肝細胞癌藥物市場規模（按藥物類別和複合年成長率分類）（2026-2033 年）

• PD-1/PD-L1抑制劑
• 蛋白酪氨酸激酶抑制劑

全球肝細胞癌藥物市場規模（按治療方法和複合年成長率分類）（2026-2033 年）

• 標靶治療
• 免疫療法
• 其他

全球肝細胞癌藥物市場規模（按治療類型和複合年成長率分類）（2026-2033 年）

• 藥物治療
• 外科手術
• 放射治療
• 化療
• 其他

全球肝細胞癌藥物市場依給藥途徑及複合年成長率分類（2026-2033 年）

• 口服
• 注射
• 其他

全球肝細胞癌藥物市場規模（按最終用戶和複合年成長率分類）（2026-2033 年）

• 醫院
• 居家醫療
• 專科診所
• 其他

全球肝細胞癌藥物市場規模（依通路分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 網路藥房
• 零售藥房

全球肝細胞癌藥物市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • GCC
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

  主要企業簡介

  • Exelixis公司（美國）
  • 默克公司（美國）
  • 阿斯特捷利康（英國）
  • 百時美施貴寶公司（美國）
  • 禮來公司（美國）
  • 新羅仁株式會社（韓國）
  • 拜耳股份公司（德國）
  • 強生全球服務有限公司（美國）
  • 輝瑞公司（美國）
  • F. Hoffmann-La Roche Ltd（瑞士）
  • 吉利德科學公司（美國）
  • 葛蘭素史克有限公司（英國）
  • 武田藥品工業株式會社（日本）
  • 安進公司（美國）
  • 北極星集團（美國）
  • Hepion Pharmaceuticals, Inc.（美國）
  • Provectus Biopharmaceuticals, Inc.（美國）

結論與建議

Global Hepatocellular Carcinoma Drugs Market size was valued at USD 1.52 Billion in 2024 and is poised to grow from USD 1.64 Billion in 2025 to USD 3.11 Billion by 2033, growing at a CAGR of 8.3% during the forecast period (2026-2033).

The global market for hepatocellular carcinoma (HCC) drugs is experiencing robust growth driven by evolving patient demographics, increased government investments in oncology, and advancements in targeted therapy research and development. Heightened governmental focus on health innovation supports the adoption of new treatments, including precision medicine tailored to liver cancer, which remains an emerging field. The growth is further propelled by improvements in early diagnosis and the rising application of immunotherapies and combination therapies within healthcare systems. Significant innovations in precision oncology are transforming HCC treatment, highlighted by biomarker-guided approaches and next-generation tyrosine kinase inhibitors (TKIs). Additionally, the emergence of artificial intelligence-driven drug discovery platforms is enhancing the rapid development and evaluation of novel immunotherapies for HCC.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatocellular Carcinoma Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hepatocellular Carcinoma Drugs Market Segments Analysis

Global Hepatocellular Carcinoma Drugs Market is segmented by Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel and region. Based on Drug Class, the market is segmented into PD-1/PD-L1 Inhibitors and Tyrosine Kinase Inhibitors. Based on Therapy Type, the market is segmented into Targeted Therapy, Immunotherapy and Others. Based on Treatment Type, the market is segmented into Medication, Surgery, Radiotherapy, Chemotherapy and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hepatocellular Carcinoma Drugs Market

The global market for drugs targeting hepatocellular carcinoma (HCC) is significantly driven by the increasing prevalence of the disease, largely due to the rise of drug-resistant chronic infections such as hepatitis B and C. The upward trend in alcohol consumption, along with a growing number of individuals suffering from nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, exacerbated by rising obesity and diabetes rates, further contributes to this growing health concern. As the patient population expands and the need for effective treatment options intensifies, there is a robust demand for both established therapies and innovative new solutions as they emerge.

Restraints in the Global Hepatocellular Carcinoma Drugs Market

The Global Hepatocellular Carcinoma Drugs market faces significant challenges primarily due to the high costs associated with immunotherapies and targeted therapies, which hinder patient access, particularly in low- and middle-income regions. Additionally, established markets implement health technology assessment policies that can prolong the reimbursement process for expensive treatments. This not only limits patient access but also impedes the timely introduction of innovative therapies, even when their clinical effectiveness has been demonstrated. Consequently, these factors contribute to a constrained market environment, reducing overall opportunities for advancement in the treatment of hepatocellular carcinoma.

Market Trends of the Global Hepatocellular Carcinoma Drugs Market

The Global Hepatocellular Carcinoma (HCC) drugs market is witnessing a notable trend with the rapid expansion of combination therapies that leverage the synergistic effects of PD-1/PD-L1 inhibitors alongside Tyrosine Kinase Inhibitors (TKIs) and anti-angiogenic agents. These innovative combinations, such as those integrating agents like lenvatinib and bevacizumab, are driving improved clinical outcomes, exemplified by significant reductions in mortality risk. This trend is further fueled by expedited regulatory approvals from agencies like the FDA and EMA, enhancing the adoption of these therapies. Consequently, this burgeoning landscape is set to reshape treatment paradigms for HCC, promoting better patient prognosis and disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Hepatocellular Carcinoma Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• PD-1/PD-L1 Inhibitors
• Tyrosine Kinase Inhibitors

Global Hepatocellular Carcinoma Drugs Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Targeted Therapy
• Immunotherapy
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Medication, Surgery
• Radiotherapy
• Chemotherapy
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Others

Global Hepatocellular Carcinoma Drugs Market Size by End-Users & CAGR (2026-2033)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Hepatocellular Carcinoma Drugs Market Size & CAGR (2026-2033)

• North America (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SillaJen, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Global Services, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Polaris Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hepion Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Provectus Biopharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations